Supplementary Figures S1-S6 from Integrative Analyses of Tumor and Peripheral Biomarkers in the Treatment of Advanced Renal Cell Carcinoma

Supplementary Figure S1 shows forest plots of PFS according to numbers of circulating cell populations in the overall trial population (both arms combined) at baseline. Supplementary Figure S2 shows forest plots of PFS with A+Ax or sunitinib according to cytokine, chemokine, or protein concentrations in peripheral blood at baseline and during treatment (cycle 2 day 1). Supplementary Figure S3 shows PFS according to metrics describing TCR repertoire change from baseline to cycle 2 day 1 with A+Ax vs sunitinib. Supplementary Figure S4 shows PFS according to updated mutation subgroup definitions and treatment group. Supplementary Figure S5 shows normalized numbers of total T cells in pretreatment tumors according to molecular subgroup. Supplementary Figure S6 shows peripheral T-cell receptor quantitation and clonality metrics at baseline and cycle 2 day 1 by mutation subgroup.